ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0030

Immune-related Diagnoses Associated with NOD2 Variants in Human Subjects: A Phenome-wide Association Study

John Davis1, Elizabeth Atkinson1, Vanessa Kronzer1, Cynthia Crowson2, Afsaneh Alavi3, John Damianos1, Loftus Edward1, Joseph Murray1, Ann Moyer1 and Filippo Pinto e Vairo1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Stewartvillle, MN, 3Department of Dermatology, Mayo Clinic, Rochester, MN

Meeting: ACR Convergence 2025

Keywords: Autoinflammatory diseases, genetics, population studies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0019–0048) Genetics, Genomics & Proteomics Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The nucleotide-binding oligomerization domain-containing protein 2 (NOD2) gene is associated with risk for several inflammatory diseases, including Crohn disease, Blau syndrome, and Yao syndrome (YAOS). Growing awareness of the heterogeneity of NOD2-associated conditions has exposed a knowledge gap about the spectrum of NOD2-related phenotypes. Our aim was to perform a phenome-wide association study (PheWAS) of NOD2 variants.

Methods: This study leveraged resources of a population-scale research program with available genomic sequencing data for nearly 100,000 participants recruited in the Midwest, Southeast, and Southwest United States. Participants were 18 to 50 years old, registered as patients at our institution, and had email and web access. Patients were excluded if they had a comorbidity that interfered with study participation, allogeneic bone marrow transplant, active hematological cancer, or non-U.S. residents. Twenty-seven NOD2 variants were pre-specified based on literature review. A sample of subjects carrying at least one pre-specified NOD2 variant was identified and matched to NOD2 variant-unexposed subjects by age, sex, residence, and length of medical records (i.e., >5 years). Subjects’ ICD-10 codes were pulled electronically for the prior 5 years and mapped to general PheWAS codes. For this analysis, one code appearance in five years was sufficient to count. PheWAS categories that appeared in fewer than 5 subjects were excluded. Chi-square tests were used to evaluate differences in the frequencies of PheWAS categories between NOD2 variant-exposed and unexposed subjects.

Results: The study included 500 subjects with NOD2 variants and 500 matched subjects without any NOD2 variants. The top four were c.2717+158C >T (IVS8+158), c.2782G >A (p.Val928Ile), c.2023C >T (p.Arg675Trp), and c.2938dup (p.Leu980ProfsTer2), with gnomAD allele frequencies 0.109 to 0.015 in descending order. NOD2 variant-exposed subjects had significantly higher frequencies than NOD2-unexposed subjects of twelve PheWAS categories (p< 0.05), including ‘rheumatoid arthritis and other inflammatory polyarthropathies’, ‘inflammatory bowel disease (IBD) and other gastroenteritis and colitis’, ‘treatment with long-term antibiotics’, ‘other signs and symptoms involving emotional state’, and ‘acute and chronic tonsilitis’ (Table 1). The most important variants driving the associations for arthritis-related diagnoses were c.2023C >T (p.Arg675Trp) and c.2717+158C >T (IVS8+158) while the most important variants for IBD-related diagnoses were c.2023C >T (p.Arg675Trp), c.2717+158C >T (IVS8+158), and c.2938dup (p.Leu980ProfsTer2) (Tables 2 and 3).

Conclusion: Our findings confirm and expand on previous reports that common NOD2 variants are associated with an increased risk of immune-related conditions. These include not only IBD and other forms of gastroenteritis and colitis, but also inflammatory arthritis, illnesses requiring long-term treatment with antibiotics, acute and chronic tonsilitis, and other related diagnoses. Further research is underway to illuminate autoinflammatory phenotypes causally related to NOD2 variants.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: J. Davis: Pfizer, 5, Remission Medical, 1, 9, 10, Rheumasense, 1, 9, 10; E. Atkinson: None; V. Kronzer: None; C. Crowson: None; A. Alavi: AbbVie, 1, 2, Almirall, 1, 2, 12, Serves on data monitoring board, Avalo Therapeutics, 1, 2, Boehringer Ingelheim, 1, 2, Cantargia, 1, 2, Hidradenitis Suppurativa Foundation, 4, 5, Incyte, 1, 2, InflaRx, 12, Serves on data monitoring board, La Roche-Posay, 5, LEO Pharma, 1, 2, National Institutes of Health, 5, Navigator Medicines, 1, 2, Novartis, 1, 2, Sanofi, 1, 2, UCB, 1, 2, Zura Bio, 12, Serves on data monitoring board; J. Damianos: ExeGi Pharma, 2, i-Health, 6; L. Edward: None; J. Murray: None; A. Moyer: None; F. Pinto e Vairo: None.

To cite this abstract in AMA style:

Davis J, Atkinson E, Kronzer V, Crowson C, Alavi A, Damianos J, Edward L, Murray J, Moyer A, Pinto e Vairo F. Immune-related Diagnoses Associated with NOD2 Variants in Human Subjects: A Phenome-wide Association Study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/immune-related-diagnoses-associated-with-nod2-variants-in-human-subjects-a-phenome-wide-association-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immune-related-diagnoses-associated-with-nod2-variants-in-human-subjects-a-phenome-wide-association-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology